Cardiff Lexington Corp (CDIX) stock
Close on Oct 19, 2026Market cap $550.31KP/E –Yield –
Cardiff Lexington Corp saw revenue fall 23.7% to $9.07M over the twelve months to Sep 30, 2026. Operating income fell 207.5% to -$2.29M, moving the operating margin from 17.9% to -25.2%. At the latest close the market valued the company at $550.31K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $550.31K
- P/E ratio
- –
- Price to sales
- 0.06
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $9.07M
- Net income
- -$11.46M
- EPS, diluted
- -$0.81
- Book value per share
- -$0.02
- Diluted shares
- 16M
Trading
- Previous close
- $0.05
- Open
- $0.05
- Day's range
- $0.03 – $0.05
- Volume
- 88,430
- Average volume (20 days)
- 70,332
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CDIX | S&P 500 | Difference | CDIX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -93.8% | +0.6% | −94.5 pts | ||
| 3 months | -96.1% | +3.4% | −99.5 pts | ||
| Year to date | -99.4% | +13.3% | −112.7 pts | ||
| 1 year | -99.3% | +16.6% | −115.9 pts | ||
| 3 years | -99.8% | +86.4% | −186.2 pts | -88.4% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.8 pts | -86.0% | +12.7% |
| 10 years | -100.0% | +318.9% | −418.9 pts | -83.7% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cardiff Lexington filed with the SEC as exhibits to Form 8-K or 6-K
About Cardiff Lexington
Services-Offices & Clinics of Doctors of Medicine
Cardiff Lexington Corporation operates as a healthcare holding company focused on acquiring and developing middle-market niche healthcare practices, primarily targeting orthopedics, spine care, and pain management. The company generates all of its operating revenue through its subsidiary, Nova Ortho and Spine, LLC, which provides traumatic injury victims with primary care evaluations, interventional pain management, emergency medical condition assessments, and diagnostic and surgical services. Its medical services cater primarily to uninsured patients and individuals involved in personal injury litigation following accidents. Additionally, the company owns Edge View Properties, Inc., a real estate subsidiary holding undeveloped residential and agricultural land.
Company profile, executives and historyCardiff Lexington stock: common questions
What is Cardiff Lexington's stock price?
CDIX closed at $0.04 on Oct 19, 2026, down 25.53% on the day.
What is Cardiff Lexington's market cap?
Cardiff Lexington was worth $550.31K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is CDIX's P/E ratio?
Cardiff Lexington lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.81), so it has no meaningful P/E ratio.
How much revenue does Cardiff Lexington make?
Cardiff Lexington reported revenue of $9.07M for the twelve months to Sep 30, 2026, down 23.7% from a year earlier.
Does Cardiff Lexington pay a dividend?
No. Cardiff Lexington has not paid a cash dividend over the last twelve months.
How has CDIX stock performed over the past year?
Including dividends, CDIX returned -99.3% over the past year, against +16.6% for the S&P 500.
Who are Cardiff Lexington's competitors?
Companies most similar to Cardiff Lexington by business, industry and size include BMGL, HLYK, SBC, EUDA, ALPS.
See a number that looks wrong?